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Effect of theophylline associated with short-acting or long-acting  
inhaled β2-agonists in patients with stable chronic obstructive  
pulmonary disease: a systematic review*
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Abstract
Objectives: To determine whether, in stable patients with chronic obstructive pulmonary disease, administration of theophylline in combi-
nation with short-acting or long-acting inhaled β2-agonists is more efficacious than is a placebo or each of these drugs used in isolation. 
Methods: A systematic review and meta-analysis were carried out. All randomized and double-blind clinical trials found in the literature 
were selected. Results: A total of eight studies were included. In comparing the effect of theophylline combined with β2-agonists to that of 
a placebo, we found a statistically significant improvement in mean FEV1 (0.27 L; 95%CI: 0.11 to 0.43) and mean dyspnea (–0.78; 95%CI: 
–1.26 to –0.29). None of the meta-analyses performed detected any difference between the results obtained using theophylline combined 
with β2-agonists and those obtained using β2-agonists alone. When the administration of theophylline combined with β2-agonists was 
compared to that of theophylline alone, there was a statistically significant improvement in mean dyspnea (–0.19; 95%CI: –0.34 to –0.04). 
Conclusion: In patients with stable chronic obstructive pulmonary disease, theophylline combined with β2-agonists is more efficacious than 
is a placebo in terms of improving FEV1 and dyspnea. In addition, theophylline combined with β2-agonists is more efficacious than is theo-
phylline in improving dyspnea. Furthermore, administration of theophylline combined with β2-agonists is no more efficacious, for any of the 
variables studied, than is the use of β2-agonists in isolation.
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Introduction
Chronic obstructive pulmonary disease (COPD) is 
considered one of the major public health problems 
in the world.(1) It was recently defined as a disease 
characterized by airflow limitation, not fully revers-
ible,(2,3) usually progressive, and accompanied by 
an abnormal pulmonary inflammatory response to 
noxious gases or particles.(4)
An efficient treatment would be one that could 
prevent the progression of the disease, reduce 
symptoms, increase exercise tolerance, prevent/treat 
complications, reduce mortality, and improve quality 
of life.(4) However, currently, there are no medica-
tions for COPD that modify the long-term decline 
in pulmonary function or reduce mortality. We will 
address, within the field of bronchodilator therapy, 
treatment with theophylline, as well as with short-
acting and long-acting inhaled β2-agonists.
The β2-agonist bronchodilators, which can be 
short-acting or long-acting, are potent and safe. 
Their principal effect consists of dilating the bronchi 
by acting directly on the β2 adrenoreceptors in the 
smooth muscle. The stimulation of these recep-
tors causes the relaxation of the smooth muscles 
through a mechanism that involves an increase in 
the intracellular concentration of cyclic adenosine 
monophosphate (cAMP).
Theophylline is the most commonly prescribed 
oral bronchodilator.(5) It is a medication that has 
been used for approximately sixty years, since it 
reduces lung hyperinflation and, consequently, 
dyspnea.(6) 
The relaxation effect on the smooth muscle 
is attributed to the inhibition of the phosphodi-
esterase, with a resulting increase in cAMP. This 
increase in cAMP also plays an important role in the 
inhibition of the inflammatory process.(7) In addi-
tion, it affects mucociliary clearance, increasing the 
ciliary beat frequency and stimulating the transport 
of secretion in the airway epithelium.(6)
The anti-inflammatory effect of theophylline is 
the object of ongoing studies. In addition to causing 
the nonselective inhibition of the phosphodieste-
rase, theophylline has been found to suppress the 
inflammatory response through the activation of 
the histone deacetylase, an enzyme that is inhibited 
by the oxidative stress occurring in patients with 
COPD. This mechanism also improves the response 
to treatment with corticosteroids and has the advan-
tage of being activated even by low concentrations 
of theophylline (5-10 µg/mL), thereby resulting in 
fewer side effects.(6)
Since bronchodilators affect different areas of 
the body, there are lines of research into whether 
the use of bronchodilators in combination presents 
a significant advantage over monotherapy,(8,9) since 
they are drugs with different mechanisms of action, 
areas of activity, time-to-onset characteristics, and 
duration of effects. Therefore, it is believed that 
using bronchodilator combinations can increase 
the degree of bronchodilation with an equivalent or 
lower number of side effects.(4)
It is difficult to compare the results of various 
studies of the use of bronchodilators in the treat-
ment of COPD, since there are methodological 
differences among such studies in terms of selection 
criteria, sample size, drug doses, methods of drug 
administration, and response evaluation criteria.(10)
Comparing the three major consensus guidelines 
for the treatment of COPD in the literature (European 
Respiratory Society – 1995, American Thoracic 
Society – 1995, and British Thoracic Society – 1997), 
one author(11) concluded that many recommenda-
tions are empiric, since they are not evidence-based. 
However, all three guidelines recommend the use of 
bronchodilators as a first line of treatment, ques-
tion the use of drug combinations, and agree that 
further studies are necessary to understand and 
treat such patients more effectively.
Given the importance of this topic, and with 
the aim of obtaining the best scientific evidence 
currently in existence in the literature about the 
therapeutic effect of theophylline combined with 
β2-agonists, we carried out this systematic review of 
randomized clinical trials.
The objective of this review was to determine 
whether, in stable patients with COPD, administra-
tion of theophylline in combination with β2-agonists 
is more efficacious than is that of a placebo or that 
of each of the two drugs used in isolation.
Methods
The present study was approved by the Ethics 
Committee of the Federal University of São Paulo/
Paulista School of Medicine (process no. 251/00). 
The randomized clinical trials included were those 
in which theophylline was used in combination 
with β2-agonists in stable patients with COPD. The 
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exclusion criteria were as follows: studies with allo-
cation concealment, inadequately described studies, 
studies of mixed populations (asthma and COPD 
patients), and studies of interventions other than 
those under study. Two independent reviewers eval-
uated the titles, abstracts, and methods sections of 
all identified reports of clinical trials. The studies that 
seemed to fulfill the inclusion criteria were selected. 
Subsequently, we built a collection of studies to be 
evaluated by the reviewers. The sources of study 
were as follows: the Excerpta Medica database, 
the Latin American and Caribbean Health Sciences 
Literature database, the Cochrane Controlled Clinical 
Trials Register, the Cochrane Airways Group Register 
of Randomized Controlled Trials, and the reference 
lists of the randomized clinical trials included.
The variables studied were continuous variables, 
which were evaluated using means and standard 
deviations for each of the groups. The following 
variables were selected for study: exercise tolerance; 
forced expiratory volume in one second (FEV1); peak 
expiratory flow; maximal inspiratory pressure (MIP); 
quality of life; symptoms; and side effects.
The statistical analysis was carried out using the 
MetaView subprogram in the Review Manager soft-
ware, available from the Cochrane Collaboration.
Results
The number of articles identified from each 
source is shown in Figure 1. The date of the last 
search in the databases was January of 2005, and 
an article from the year 2001 was located through 
a handsearch.
Of the 848 articles initially selected, a total of 
822 were excluded, since they did not involve the 
group or intervention of interest. Therefore, twenty-
six studies were subjected to the inclusion and 
exclusion criteria previously defined, after which 
only eight remained. Table 1 shows the principal 
characteristics of the articles included.
Quality of the studies included
In the allocation sequence, it was not mentioned 
how the respective sample sizes of the eight studies 
were calculated or if there was concern about 
doing so. All were double-blind studies and were 
adequately described. As for allocation conceal-
ment, it was mentioned in all of the texts that the 
studies were randomized, although the randomiza-
tion procedures were not described. Only one of the 
studies(9) was a parallel study. The remaining seven 
were crossover trials.
In two of the eight studies, there were no 
losses.(12,13) In the remaining studies, losses ranged 
from 10.7 to 29.6%. The instrument known as the 
quality scale(14) is used to evaluate the merit of studies, 
taking into consideration three factors: randomiza-
tion, masking, and the rate of dropouts/losses. The 
eight studies were randomized (although the way 
in which that was carried out was not described), 
Articles identified in the references 
of the studies included 
n = 3
Articles found in electronic 
databases
n = 848
Handsearch
n = 1
Articles found (cumulative)
n = 848
Articles not selected (cumulative)
n = 822
Studies selected
n = 26
Studies included
n = 8
Studies excluded
n = 18
Figure 1 - Flowchart of the systematic review - n: number of articles.
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double-blind, and adequately described. In addition, 
any losses were explained. All scored three points. 
This scale is not used to include or exclude studies 
from a systematic review. However, it is possible to 
use it to group homogeneous studies for the sensi-
tivity analysis portion of a meta-analysis.
Table 1 - Principal characteristics of the studies included.
Study Duration Variables 
 
Definition of 
COPD
Sample
size
Intervention
Dullinger 
et al.(12)
5 weeks FVC and FEV1
12-min walk test and 
incremental test
Dyspnea
FEV1 < 1.5 L and 
FEV1/FVC < 60%
10 Long-acting 
theophylline 
(10-15 µg/mL)  
Short-acting metapro-
terenol (2×/day)
Guyatt 
et al.(30)
8 weeks FVC, FEV1 and PEF
6-min walk test
Dyspnea and Quality 
of life
FEV1 < 70% and 
FEV1/VC < 0.7
19 Long-acting 
theophylline
(12.3 ± 2.9 µg/mL)
Short-acting 
salbutamol
(200 µg - 4×/day)
Guyatt 
et al.(19)
8 weeks FVC and FEV1
6-min walk test
Dyspnea and Quality 
of life
FEV1 < 70% and 
FEV1/VC < 0.7
24 Long-acting 
theophylline
Short-acting albuterol
(200 µg-4×/day)
Jaeschke 
et al.(16)
8 weeks FVC and FEV1
Maximal inspiratory 
pressure
Dyspnea
FEV1 < 70% and 
FEV1/VC < 0.7
24 Long-acting 
theophylline
(12.3 ± 3.4 µg/mL)
Short-acting 
salbutamol
(200 µg-4×/day)
Karpel 
et al.(13)
45 days  
(4 regimens on 
4 non-consecutive 
days)
FVC and FEV1
Side effects
As defined by the 
American Thoracic 
Society 
48 Short-acting 
theophylline 
(12-18 µg/mL)
Short-acting albuterol 
(2× 180 µg)
Taylor 
et al.(15)
12 weeks FVC, FEV1 and PEF
Symptoms diary
Productive cough 
yielding sputum 
for 3 months for 2 
consecutive years
25 Long-acting 
theophylline
(10-15 µg/mL)
Short-acting 
salbutamol
(200 µg-4×/day)
Thomas 
et al.(17)
56 days Spirometry and PEF
Symptoms diary
Patients aged 70 
years or less and 
FEV1 < 60% and 
FEV1/FVC < 0.7
12 Long-acting 
theophylline
(10 µg/mL)
Short-acting salb-
utamol 
(2× 200 µg)
ZuWallack 
et al.(9)
12 weeks Spirometry and PEF
Dyspnea
Symptoms diary
Quality of life
Satisfaction with 
treatment
FEV1 ≥ 0.7 L, 
≤ 65% and FEV1/FVC 
≤ 70%
962 Long-acting 
theophylline
(10-20 µg/mL)
Long-acting salmeterol 
(42 µg) 
FEV1: forced expiratory volume in one second; VC: vital capacity; FVC: forced vital capacity; PEF: peak expiratory flow.
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Results of the outcomes studied
Theophylline combined with β2-agonists vs. 
placebo
Of the 156 patients included in seven crossover 
clinical trials with continuous variables, 156 received 
theophylline combined with β2-agonists, and 
156 received placebos. The individuals allocated 
to the group that received theophylline combined 
with β2-agonists, in comparison to those allocated 
to the group that received placebos, presented the 
following results:
FEV1 (L): difference in weighted means (rand-
omized effect model) 0.27; 95% confidence interval 
(0.11 to 0.43); p = 0.0007; and test of heterogeneity 
p = 0.96. These results are statistically significant 
and are based on three studies that had 48 indi-
viduals per group(15-17) (Table 2).
Dyspnea: difference in standardized means 
(randomized effect model) −0.78; 95% confidence 
interval (−1.26 to −0.29); p = 0.002; and test of 
heterogeneity p = 0.58. These results are statistically 
significant and are based on two studies that had 
36 individuals per group(16,17) (Table 3).
Theophylline combined with β2-agonists vs. 
β2-agonists in isolation
Of the 719 patients included in eight clinical 
trials, 361 received theophylline combined with 
β2-agonists and 358 received β2-agonists in isolation. 
There were no statistically significant differences in 
any of the variables studied.
Theophylline combined with β2-agonists vs. 
theophylline in isolation
Of the 926 patients included in eight clinical 
trials, 462 received theophylline combined with 
β2-agonists and 464 received theophylline in isola-
tion. The individuals allocated to the group that 
received theophylline combined with β2-agonists, 
in comparison to those allocated to the group that 
received theophylline in isolation, presented the 
following results:
Dyspnea: difference in standardized means 
(randomized effect model) –0.19; 95% confidence 
interval (–0.34 to –0.04); p = 0.01; and test of 
heterogeneity p = 0.79. These results are statisti-
cally significant and are based on three studies that 
had a total of 336 individuals in the groups that 
received theophylline combined with β2-agonists 
and 344 in the groups that received theophylline in 
isolation(9,16,17) (Table 4).
Discussion
The results of this systematic review revealed a 
significant improvement in FEV1 and dyspnea with 
the use of theophylline combined with β2-agonists 
in relation to the use of a placebo, as well as an 
improvement in dyspnea in the group of patients 
who were treated with theophylline combined with 
Table 2 - Meta-analysis of three studies comparing the effect of theophylline combined with β2-agonists to that of 
a placebo in patients with COPD. Presentation of the variable FEV1 (L) through the difference in weighted means and 
95% confidence intervals (randomized effect model). 
Study, year Theo + β2 group PL group Difference in weighted 
means (95% CI)
Weight 
(%)
95% CI
n/mean ± SD
Theo + β2 vs. PL
Jaeschke et al.(16) 24/1.07 ± 0.34 24/0.81 ± 0.36 62.7 0.26 (0.06 to 0.46)
Taylor et al.(15) 12/1.38 ± 0.56 12/1.14 ± 0.59 11.6 0.24 (–0.22 to 0.70)
Thomas et al.(17) 12/1.34 ± 0.42 12/1.03 ± 0.35 25.7 0.31 (0.00 to 0.62)
Total 48 48 100.0 0.27 (0.11 to 0.43)
Test of heterogeneity χ2 = 0.09, df = 2, p = 0.96
Z-test of overall effect = 3.38, p = 0.0007
Theo: theophylline, PL: placebo; 95% CI: 95% confidence interval; n: number; SD: standard deviation; df: degrees of freedom; χ2: 
chi-square test.
-1 -5 0 5 1
Favorable to 
Theo  + B2
Favorable to 
PL
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β2-agonists in comparison to the group of patients 
who used theophylline in isolation.
The analysis of pulmonary function must 
take into account that the function tests, despite 
being carried out with the patient at rest and not 
reproducing the alterations that occur during exer-
cise,(18) are still the gold standard for the diagnosis 
and evaluation of COPD, since they are the most 
reproducible, standardized, and objective way of 
measuring airflow limitation.(4) 
We found statistically significant differences 
in FEV1 (L) when we compared the effect of theo-
phylline combined with β2-agonists to that of a 
placebo.(15-17)
Other authors(15) studied the effect of theo-
phylline and of salbutamol, used in isolation or in 
combination, in 25 patients with COPD and revers-
ibility of FEV1 ≤ 10%. The study was carried out 
in four phases of three weeks each: theophylline + 
salbutamol; theophylline; salbutamol; and placebo. 
In each phase, they evaluated pulmonary function 
test results (spirometry: prior to and after each 
intervention, and peak expiratory flow: daily), as 
well as the symptoms diaries kept by the patients. 
Table 3 - Meta-analysis of two studies comparing the effect of theophylline combined with β2-agonists to that of a 
placebo in patients with COPD. Presentation of the results of the variable dyspnea through the difference in weighted 
means and a 95% confidence interval (randomized effect model).
Study, year Theo + β2 group PL group Difference in weighted 
means (95% CI)
Weight 
(%)
95% CI
n/mean (SD)
Theo + β2 vs. PL
Jaeschke et al.(16) 24/–19.40 ± 4.60 24/−14.6 ± 6.10 65.6 0.87 (−1.47 to −0.28)
Thomas et al.17 12/0.53 ± 0.84 12/1.14 ± 1.14 34.4 −059 (−1.41 to 0.23)
Total 36 36 100.0 −0.78 (−1.26 to −0.29)
Test of heterogeneity χ2 = 0.31, df = 1, p = 0.58
Z-test of overall effect = 3.16, p = 0.02
Theo: theophylline, PL: placebo; 95% CI: 95% confidence interval; n: number; SD: standard deviation; df: degrees of freedom; χ2: 
chi-square test.
-4 -2 0 2 4
Favorable to 
Theo + B2
Favorable
to PL
Table 4 - Meta-analysis of three studies comparing the effect of theophylline combined with β2-agonists to that 
of theophylline in isolation in patients with COPD. Presentation of the results of the variable dyspnea through the 
difference in weighted means and 95% confidence intervals (randomized effect model). 
Study, year Theo + β2 group Theo group Difference in weighted  
means (95% CI)
Weight 
(%)
95% CI
n/mean (SD)
Theo + β2 vs. Theo
Jaeschke et al.(16) 24/−19.40 ± 4.60 24/−17.50 ± 6.50 7.0 −0.33 (0.90 to 0.24)
Thomas et al.(17) 12/0.53 ± 0.84 12/0.84 ± 0.81 3.5 −0.36 (−1.17 to 0.45)
Zuwallack et al.(9) 300/−6.40 ± 1.73 308/−6.10 ± 1.75 89.5 −0.33 (−0.33 to −0.01)
Total 336 344 100.0 0.19 (−0.34 to −0.04)
Test of heterogeneity χ2 = 0.46, df = 2, p = 0.79
Z-test of overall effect = 2.47, p = 0.01
Theo: theophylline; 95% CI: 95% confidence interval; n: number; SD: standard deviation; df degrees of freedom; χ2: chi-square 
test.
-5 -1 0 1 5
Favorable to 
Theo
Favorable to 
Theo + B2
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The authors found that using the drugs in combi-
nation produced a significant improvement in the 
spirometric values (p < 0.001).
In other studies,(16) the samples consisted of 
24 stable patients with COPD and reversibility of 
FEV1 ≤ 35%. The authors analyzed the effects of 
theophylline and of salbutamol on pulmonary func-
tion and dyspnea during activities of daily living. In 
four two-week periods, the patients were submitted 
to the following treatments: salbutamol; theophyl-
line; theophylline combined with salbutamol; and 
placebo. The use of theophylline combined with 
salbutamol was found to produce a significant 
increase in FEV1 (p < 0.001) in comparison to the 
use of a placebo.
The last study included,(17) which contributed to 
the significant improvement in FEV1 in this meta-
analysis, analyzed 12 stable patients with COPD 
(FEV1 = 1.09 ± 0.35 L) and bronchodilator revers-
ibility of FEV1 ≤ 15%. The duration of the study was 
56 days, divided into four two-week phases. The 
interventions were as follows: theophylline; salb-
utamol; theophylline + salbutamol; and placebo. 
Spirometry was performed at the end of each phase. 
In the patients treated with the drugs, FEV1 improved 
by 13.5% in those receiving theophylline, 16.2% 
in those receiving salbutamol, and 31.3% in those 
receiving the two drugs in combination.. Therefore, 
use of the theophylline + salbutamol combination 
resulted in a significant improvement.
The FEV1 was found to be the most common vari-
able in the clinical trials, despite being expressed in 
liters in some studies(12,13,15-17,19) and as a percentage 
of predicted in others.(9,15) Therefore, of the eight 
articles included, seven studied FEV1. However, 
certain studies were excluded from the statistical 
analysis because of inappropriate presentation of 
the data(12,19) or differences in methodology, such 
as that observed in one study,(13) whose authors 
divided the sample into patients with FEV1 ≤ 0.5 L 
and patients with FEV1 ≥ 0.5 L.
The analysis of the theophylline combined with 
β2-agonists vs. theophylline in isolation groups, 
together with that of the theophylline combined 
with β2-agonists vs. β2-agonists in isolation groups, 
revealed that the response to the use of the drugs in 
combination was favorable only when compared to 
the response obtained with the use of theophylline 
in isolation.
It is important to emphasize that, in the studies 
that revealed no significant improvement in pulmo-
nary function, benefits in quality of life,(20) as well as 
symptom improvement,(21,22,24-26) were observed.
As for dyspnea, we should bear in mind that this 
is one of the principal complaints of patients with 
COPD. This is a subjective report, which is related to 
various factors, from physiological to sociocultural 
ones. This is considered to be the most highly-
valued symptom in the literature.(27)
It is believed that bronchodilators produce dila-
tion of the small airways, with a consequent decrease 
in air trapping, which results in increased muscle 
strength, reduced dyspnea, and improved exercise 
tolerance in patients with COPD.(27)
We obtained statistical significance in the 
differences between the following pairs of 
groups: theophylline combined with β2-agonists 
vs. placebo;(16,17) and theophylline combined with 
β2-agonists vs. theophylline in isolation.(9,16,17) These 
findings are of great clinical importance for patients 
with COPD, since reduced dyspnea is directly related 
to improved quality of life in such patients.
In one study,(16) the principal objective was to 
evaluate dyspnea during activities of daily living in 
patients with COPD being treated with theophyl-
line and salbutamol, in combination or not. This 
evaluation was carried out using one part of the 
Chronic Respiratory Questionnaire (CRQ), which is 
an instrument used to assess health-related quality 
of life, in which there are 5 questions on a 7-point 
scale (ranging from 5 to 35 points), an overall score 
of 1 signifying severe dyspnea and an overall score 
of 7 signifying no dyspnea. A significant negative 
correlation was found between dyspnea and FEV1, 
as well as between dyspnea and MIP (p < 0.001 
for both), and it was concluded that the degree of 
dyspnea during activities of daily living is lower, 
due to increased muscle strength and increased 
airway diameter, in patients receiving theophylline 
combined with salbutamol.
One group of authors,(17) using a 5-point symp-
toms diary scale (0 = none, and 4 = intolerable), 
described the following symptoms: dyspnea, cough, 
secretion, and bronchoconstriction. The use of 
theophylline + salbutamol resulted in a signifi-
cant decrease in dyspnea, as well as a significant 
improvement in bronchoconstriction. No differ-
ences were found between groups regarding cough 
or production of secretion.
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A randomized, double-blind, parallel-group 
study(9) of 962 stable patients with COPD evalu-
ated the efficacy of theophylline and salmeterol in 
improving pulmonary function and symptoms as 
well as in preventing exacerbations. The duration of 
the study was twelve weeks, and the patients were 
divided into three groups: salmeterol; theophylline; 
and theophylline + salmeterol. The patients were 
instructed to keep a diary to record peak expiratory 
flow values and symptoms scores. Health-related 
quality of life questionnaires were applied by 
professionals during the evaluations made at the 
clinic at weeks 4, 8, and 12. Dyspnea was evaluated 
using two indexes: the baseline dyspnea index (BDI) 
and the transitional dyspnea index (TDI). The use of 
theophylline combined with salmeterol resulted in a 
significant improvement in symptoms (p = 0.023). 
As for dyspnea, the biggest difference was found 
in relation to the group that used theophylline in 
isolation (p < 0.048).
All three studies demonstrated a significant 
decrease in dyspnea after the use of theophyl-
line combined with β2-agonists in comparison to 
the other interventions. We had great difficulty in 
analyzing this variable due to the variations among 
the methods used. However, its evaluation was 
possible through statistical standardization, taking 
into account the significance of the results found 
in each study.
According to one study,(28) dyspnea can be meas-
ured during activities of daily living and during 
specific tests (for example, after the walk test). The 
forms of measurement accepted by the American 
Association of Cardiovascular and Pulmonary 
Rehabilitation are as follows: for activities of daily 
living, the BDI and the TDI, as well as the dyspnea 
portion of the CRQ; and for specific tests, the 
0-10 Borg scale or the visual analog scale.
In the studies already described, we found the 
use of the CRQ and the use of the dyspnea indexes 
(the TDI and the BDI). However, some authors(17) used 
another scale to evaluate this variable. Although 
another two studies(12,30) evaluated dyspnea, they 
could not be used in the statistical analysis since 
their results were not adequately described. We can 
compare the results of one study(12) with those of 
this systematic review, since we found no statistically 
significant differences in the comparison between 
the group treated with theophylline + β2-agonists 
and the group treated with β2-agonists in isolation.
Given the large number of scales and indexes, it 
seems that there is great interest in studying dyspnea 
in patients with COPD. However, as was observed, 
there is considerable variation among studies in 
terms of the approach taken in evaluating dyspnea, 
and this hinders the comparative analysis, making it 
difficult to reach a conclusion on this subject.
As for peak expiratory flow and MIP, due to 
the small number of studies found, there is no 
convincing evidence that the use of theophylline 
combined with β2-agonists results in improvement 
in these parameters. 
Another two variables that are important for 
patients with COPD are exercise tolerance and 
quality of life. Exercise tolerance was studied using 
the 6-minute walk test,(19,30) the 12-minute walk 
test, and the incremental test on a cycle ergom-
eter.(12) Quality of life was determined, by one group 
of authors,(19,30) using the CRQ. All of these variables 
are accepted in the literature. Unfortunately, we 
could not use them in our statistical analysis since 
they were not adequately described, having been 
published without the standard deviations.
The side effects of the use of the drugs were 
reported in the studies but were not described in 
terms of any clinical or statistical significance. The 
most commonly cited study(9) emphasized the dele-
terious effect of theophylline on the gastrointestinal 
tract, and nausea was the principal complaint. In 
all of the studies, the authors mentioned that the 
use of the drugs in combination has the benefit of 
minimizing side effects. 
The present systematic review allows us to 
conclude the following regarding in stable patients 
with COPD: administration of theophylline combined 
with β2-agonists is more efficacious than is a placebo 
in terms of improving FEV1 and dyspnea; adminis-
tration of theophylline combined with β2-agonists 
is more efficacious than is the use of theophyl-
line in isolation in terms of improving dyspnea; 
and administration of theophylline combined with 
β2-agonists is no more efficacious, for any of the 
variables studied, than is the use of β2-agonists in 
isolation.
However, in clinical decision making, the data 
in the literature constitute only one of the aspects 
that, in conjunction with clinical experience and the 
status/responses of individual patients, ultimately 
define the approach to treatment.
Effect of theophylline associated with short-acting or long-acting inhaled β2-agonists  
in patients with stable chronic obstructive pulmonary disease: a systematic review
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